Publications by authors named "A M Starzer"
Background: Brain metastases (BMs) are common in human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer, increasing morbidity and mortality. Systemic therapy for BMs can be effective, with the triple combination of trastuzumab, capecitabine, and tucatinib being a potential standard. More recently, intracranial activity of antibody-drug conjugates has been reported, but the size of individual studies has been small.
View Article and Find Full Text PDFArticle Synopsis
- * In a study of 791 cancer patients undergoing anti-cancer therapies, 17.6% experienced clinically relevant bleeding (CRB), with significant types including gastrointestinal and tumor-related bleeding.
- * Bleeding events, particularly in those without anticoagulation, were linked to higher mortality rates; patients experiencing CRB had a 5.80 times higher risk of all-cause death compared to those who did not bleed.
Article Synopsis
- Brain metastases (BM) are a critical issue for patients with HER2-positive metastatic breast cancer, necessitating better treatment options; the study examined the effectiveness of the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) compared to trastuzumab emtansine.* -
- In the TUXEDO-1 trial involving patients with HER2-positive BC and active BM, the results showed a median progression-free survival (PFS) of 21 months and an overall survival (OS) that had not been reached at 26.5 months of follow-up, indicating positive outcomes for T-DXd.* -
- No new safety concerns emerged throughout the trial, with fatigue being the most reported
Immune checkpoint inhibitors (ICI) and tyrosine kinase inhibitors (TKI) have gained therapeutical significance in cancer therapy over the last years. Due to the high efficacy of each substance group, additive or complementary effects are considered, and combinations are the subject of multiple prospective trials in different tumor entities. The majority of available data results from clinical phase I and II trials.
View Article and Find Full Text PDFBackground: DNA methylation profiles have emerged as potential predictors of therapeutic response in various solid tumors.
Objective: This study aimed to analyze the DNA methylation profiles of patients with stage IV metastatic melanoma undergoing first-line immune checkpoint inhibitor treatment and evaluate their correlation with a radiological response according to immune-related Response Evaluation Criteria in Solid Tumors (iRECIST).
Methods: A total of 81 tissue samples from 71 patients with metastatic melanoma (27 female, 44 male) were included in this study.